A vaccine given in the skin to prevent tuberculosis appears to reach much deeper than expected. In a year-long study published in Communications Medicine, investigators led by Mass General Brigham found that the Bacillus Calmette-Guerin (BCG) vaccine increased the responsiveness of immune cells in the fluid surrounding the brain and spinal cord, and shifted Alzheimer's-related biomarkers in older adults who had no biomarker evidence of Alzheimer's pathology. In participants who already showed that pathology, the biomarker changes did not appear.
The result matters because it offers a possible biological mechanism behind something researchers have noticed but could not explain: people who receive BCG have shown lower rates of Alzheimer's disease in earlier retrospective studies, preclinical work, and randomized trials. BCG is known to produce what immunologists call trained immunity, a broad recalibration of immune defenses that boosts responses to unrelated infections and can even affect blood sugar control. Until now, nearly all of that work looked at immune cells in blood, leaving open the question of whether the effect extended to the central nervous system compartment. This study suggests it does.
The split between people with and without Alzheimer's pathology is the detail worth watching. It hints that any protective effect might depend on intervening before the disease process is well underway, which is where senior author Steven Arnold, MD, managing director of the Interdisciplinary Brain Center at the Mass General Brigham Neuroscience Institute, said the next efforts should focus. Arnold framed the broader lesson as evidence that the immune system and the brain are more tightly linked than previously assumed.
This is early-stage mechanistic work, not proof that BCG prevents dementia. Arnold has called for larger, controlled studies, particularly prevention trials aimed at preserving brain health before significant disease develops. BCG's other off-target uses remain under active investigation at Mass General Brigham, including ongoing Phase III trials in type 1 diabetes and earlier trials in COVID-19.